Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
June 3, 2019Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
-
May 23, 2019Targovax to fully focus on ONCOS oncolytic virus program
-
May 23, 2019Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
-
May 9, 2019Targovax ASA: First quarter 2019 results
-
May 8, 2019Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma